Physician profile
Haley C Watson
NPI 1528822251
$1,621.68
in general payments reported to CMS, 2019-2025
23 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $451 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $280.48 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $256.78 | 2024-2025 | |
| Pfizer INC. | $175.17 | 2025 | |
| Glaxosmithkline, LLC. | $165.34 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $141.34 | 2024-2025 | |
| Lilly USA, LLC | $81.01 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.01 | 2024-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.49 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $52.10 | 2024-2025 | Trintellix, Glassia |
| Verona Pharma, INC. | $50.22 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $38.20 | 2025 | Rexulti |
| Astellas Pharma US INC | $37.52 | 2024 | Veozah |
| Exact Sciences Corporation | $37.47 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $31.69 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $24.72 | 2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $23.38 | 2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $19.40 | 2024 | Evkeeza |
| Novo Nordisk INC | $18.04 | 2025 | Wegovy |
| Ardelyx, INC. | $17.57 | 2024 | Ibsrela |
| Tris Pharma INC | $16.43 | 2025 | Dyanavel Xr |
| Shield Therapeutics INC | $16.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.01 | 2025 | Jardiance |
| Corium, LLC | $9.02 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.